MangoRx Responds to and Refutes Recent Claims Made by Eli Lilly
Mangoceuticals, Inc. (MGRX)
Company Research
Source: GlobeNewswire
Dallas, Texas, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men’s health and wellness products via a secure telemedicine platform learned earlier this morning that Eli Lilly has made certain public claims alleging, and has stated that it has filed a lawsuit against MangoRx claiming, that MangoRx improperly copied its weight-loss medicine, Zepbound and Mounjaro. MangoRx strongly refutes any and all claims made by Eli Lilly regarding the sale of compounded tirzepatide. MangoRx believes it has strong arguments against Eli Lilly’s claims and intends to vigorously defend itself in this matter. MangoRx’s focus is, and will continue to be, providing access to safe and efficacious products to serve patients who have been deemed medically appropriate to consume its products by U.S. licensed practitioners. MangoRx remains committed to its mission and plans to continue to enhance pat
Show less
Read more
Impact Snapshot
Event Time:
MGRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MGRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MGRX alerts
High impacting Mangoceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
MGRX
News
- Mangoceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewswire
- MangoRx Announces Formation of Strategy and Alternatives CommitteeGlobeNewswire
- MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT AS PART OF NASDAQ COMPLIANCE PLANGlobeNewswire
- MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss SolutionsGlobeNewswire
- MangoRx Addresses $49.3 Billion Global GLP-1 Market With Launch of Oral Semaglutide for Advanced Weight Loss TreatmentGlobeNewswire
MGRX
Sec Filings
- 11/14/24 - Form 10-Q
- 11/12/24 - Form 4
- 11/12/24 - Form 8-K
- MGRX's page on the SEC website